DexCom, Inc. (DXCM)

Outside of a handful of highflying technology stocks, U.S. stocks have been practically flat in 2023, but on Wall Street, some analysts remain as bullish as ever.

As of September 19, S&P 500 healthcare stocks were down 3.2% for the year. Of the 11 sectors, its year to date (YTD) performance is the second worst only behind utilities.

Vertex has almost no weak spots thanks to a solid core franchise and several promising programs. DexCom is helping improve the lives of diabetes patients, and the company still has lots of room to gro...

A remarkable 30-year bull run for the Nasdaq 100 saw it gain nearly 4,000% by 2020. But, the party came to a screeching halt when the pandemic hit.

DexCom's (DXCM) latest CGM sensor, DexCom ONE, secures reimbursement coverage in France, bringing the real-time CGM sensor to half a million diabetes patients in the country.

The notable increase in DexCom's revenues over recent quarters has also contributed to the stock recovery.

A Raymond James analyst cut his price target on the specialty medical device maker. It was the second such price target cut so far this month.

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

DexCom's (DXCM) shares have rallied nearly 7% over the past week, presumably on positive outlook for its CGM devices amid rising competition.

We believe DexCom stock (NASDAQ: DXCM) is a better healthcare pick than Intuitive Surgical stock (NASDAQ: ISRG).